Li, W., Wang, T., Xu, H., Liu, Q., Zhang, H., Yang, Y., Sun, X., Yu, H., Gu, Y., Li, H., Ding, H., Wang, D.

Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial

25 de May de 2025 by Li, W., Wang, T., Xu, H., Liu, Q., Zhang, H., Yang, Y., Sun, X., Yu, H., Gu, Y., Li, H., Ding, H., Wang, D.

Background
Endoscopic surgery has become the first-line treatment for surgically resectable recurrent nasopharyngeal carcinoma (rNPC), but it is associated with a high risk of postoperative tumor progression. Currently, there is a lack of effective an…